Coronary angiography following transcatheter aortic valve replacement: Insights from the SWEDEHEART registry.
TAVR
aortic regurgitation
aortic stenosis
coronary artery disease
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
revised:
26
06
2024
received:
27
04
2024
accepted:
20
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
aheadofprint
Résumé
Transcatheter aortic valve replacement (TAVR) is the most common treatment in patients with symptomatic severe aortic stenosis (AS). As concomitant coronary artery disease is common in AS patients, access to the coronary arteries following TAVR is of increasing importance. This study evaluated the incidence and risk factors for unplanned coronary angiography following TAVR and, using fluoroscopic time as a surrogate, analyzed the complexity of coronary artery cannulation. All patients who underwent TAVR in Sweden between 2008 and 2022 were identified using the SWEDEHEART registry. The cumulative incidence of coronary angiography after TAVR was analyzed with mortality as a competing risk. Angiography and PCI complexity were analyzed using fluoroscopic time and compared across different transcatheter heart valve designs. Out of 9806 patients, 566 subsequently required coronary angiography. The incidence was highest for three-vessel and/or left main disease. Younger age, the extent of prior coronary artery disease, and peripheral vascular disease were associated with an increased risk of coronary angiography. Fluoroscopy time was increased in TAVR patients compared to the control group with the longest fluoroscopy times observed in cases involving supra-annular and self-expanding valves. The incidence of coronary angiography following TAVR is still low. Younger patients and patients with concomitant coronary artery disease have a higher risk. Procedural time is longer in patients with a previous THV replacement. As TAVR is emerging as the first-line treatment in patients with longer life expectancy, facilitating coronary access is an important factor when considering which THV device to implant.
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter aortic valve replacement (TAVR) is the most common treatment in patients with symptomatic severe aortic stenosis (AS). As concomitant coronary artery disease is common in AS patients, access to the coronary arteries following TAVR is of increasing importance.
OBJECTIVES
OBJECTIVE
This study evaluated the incidence and risk factors for unplanned coronary angiography following TAVR and, using fluoroscopic time as a surrogate, analyzed the complexity of coronary artery cannulation.
METHODS
METHODS
All patients who underwent TAVR in Sweden between 2008 and 2022 were identified using the SWEDEHEART registry. The cumulative incidence of coronary angiography after TAVR was analyzed with mortality as a competing risk. Angiography and PCI complexity were analyzed using fluoroscopic time and compared across different transcatheter heart valve designs.
RESULTS
RESULTS
Out of 9806 patients, 566 subsequently required coronary angiography. The incidence was highest for three-vessel and/or left main disease. Younger age, the extent of prior coronary artery disease, and peripheral vascular disease were associated with an increased risk of coronary angiography. Fluoroscopy time was increased in TAVR patients compared to the control group with the longest fluoroscopy times observed in cases involving supra-annular and self-expanding valves.
CONCLUSIONS
CONCLUSIONS
The incidence of coronary angiography following TAVR is still low. Younger patients and patients with concomitant coronary artery disease have a higher risk. Procedural time is longer in patients with a previous THV replacement. As TAVR is emerging as the first-line treatment in patients with longer life expectancy, facilitating coronary access is an important factor when considering which THV device to implant.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Skånes universitetssjukhus
Organisme : Sahlgrenska Universitetssjukhuset
Informations de copyright
© 2024 The Author(s). Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic‐valve replacement in low‐risk patients at five years. N Engl J Med. 2023;389(21):1949‐1960. doi:10.1056/NEJMoa2307447
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695‐1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic‐valve replacement with a self‐expanding valve in low‐risk patients. N Engl J Med. 2019;380:1706‐1715.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS). Revista Española de Cardiología (English Edition). 2022;75:524.
Isselbacher EM, Preventza O, Hamilton Black J, et al. ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):e334‐e482.
Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol. 2022;80:2054‐2056.
Paradis J‐M, Fried J, Nazif T, et al. Aortic stenosis and coronary artery disease: what do we know? What don't we know? A comprehensive review of the literature with proposed treatment algorithms. Eur Heart J. 2014;35:2069‐2082.
Okuno T, Demirel C, Tomii D, et al. Long‐term risk of unplanned percutaneous coronary intervention after transcatheter aortic valve replacement. EuroIntervention. 2022;18:797‐803.
Silva G, Espada Guerreiro C, Goncalves Teixeira P, et al. Feasibility of coronary angiography after TAVR. Eur Heart J. 2021;42:ehab724.2082.
Hermiller JB, Gunnarsson CL, Ryan MP, Moore KA, Clancy SJ, Irish W. The need for future coronary access following surgical or transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2021;98:950‐956.
Tarantini G, Nai Fovino L, Scotti A, et al. Coronary access after transcatheter aortic valve replacement with commissural alignment: the ALIGN‐ACCESS Study. Circ Cardiovasc Interv. 2022;15:e011045.
Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement. JACC: Cardiovasc Interv. 2020;13:2542‐2555.
Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish web‐system for enhancement and development of evidence‐based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617‐1621.
Anon. Årsrapport 2022 Accessed October 30 2023. https://www.ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh.
Antman EM. Improving care at the population and individual level: lessons from SWEDEHEART. Eur Heart J. 2018;39:3777‐3779.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496‐509.
Perrin N, Fassa A, Baroz A, et al. Complexity assessment and technical aspect of coronary angiogram and percutaneous coronary intervention following transcatheter aortic valve implantation. Cardiol J. 2022;29:197‐204.
Stefanini GG, Cerrato E, Pivato CA, et al. Unplanned percutaneous coronary revascularization after TAVR. JACC: Cardiovasc Interv. 2021;14:198‐207.
Khan M, Senguttuvan NB, Krishnamoorthy P, et al. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement with Medtronic self‐expanding prosthesis: insights from correlations with computer tomography. Int J Cardiol. 2020;317:18‐24.
Nai Fovino L, Scotti A, Massussi M, et al. Incidence and feasibility of coronary access after transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2020;96(5):E535‐E541. doi:10.1002/ccd.28720
Dworeck C, Redfors B, Völz S, et al. Radial artery access is associated with lower mortality in patients undergoing primary PCI: a report from the SWEDEHEART registry. Eur Heart J Acute Cardiovasc Care. 2020;9:323‐332.
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9‐19.
Tarantini G, Nai Fovino L, D'Errigo P, et al. Factors influencing the choice between transcatheter and surgical treatment of severe aortic stenosis in patients younger than 80 years: results from the OBSERVANT study. Catheter Cardiovasc Interv. 2020;95(6):E186‐E195. do:10.1002/ccd.28447
Zaid S, Bapat VN, Sathananthan J, et al. Challenges and future directions in redo aortic valve reintervention after transcatheter aortic valve replacement failure. Circulation: Cardiovasc Interv. 2023;16(11). doi:10.1161/CIRCINTERVENTIONS.123.012966
De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR‐in‐TAVR as evaluated by multidetector computed tomography. JACC: Cardiovasc Interv. 2020;13:2528‐2538.